Le Lézard
Classified in: Health
Subject: CCA

InMode to Report Third Quarter 2019 Financial Results on November 5, 2019


YOQNEAM, Israel, Oct. 10, 2019 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it will release its results for the third quarter of 2019 before the Nasdaq market opens on Tuesday, November 5, 2019.

InMode logo (PRNewsfoto/InMode)

Mr. Moshe Mizrahy, Chairman and Chief Executive Officer, and Mr. Yair Malca, Chief Financial Officer, will host a conference call that same day, November 5, 2019, at 9 a.m. Eastern Time.

To attend the conference call, please dial one of the following teleconferencing numbers. Please begin by placing your call five minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

U.S. Toll-Free Dial-in Number: 1-866-777-2509
Israel Toll- Free Dial-in Number: 1-80-921-2373
International Dial-in Number: 1-412-317-5413
At:
9 a.m. Eastern Time
6 a.m. Pacific Time
4 p.m. Israel Time

The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/.

A replay of the conference call will be available from November 5, 2019 at 12 p.m. Eastern Time to November 19, 2019 at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: 

Replay Dial-in TOLL-FREE: 1-877-344-7529
Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 10135351
A replay will also be available for 90 days on InMode's website at https://inmodemd.com/investors/.

About InMode 
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio-frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

Investor Contact:
MS-IR LLC
Miri Segal ? Scharia
[email protected]
Tel: 917-607-8654

SOURCE InMode


These press releases may also interest you

at 05:45
The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to  ResearchAndMarkets.com's offering....

at 05:45
The Gross Law Firm issues the following notice to shareholders of InMode Ltd. . Shareholders who purchased shares of INMD during the...

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:20
IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced that China National Medical Products Administration (NMPA) has approved the...

at 05:15
The "Flow Cytometry Markets. Forecasts by Technology, Product and Application. With Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. The technology is moving faster than the market. Find the...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....



News published on and distributed by: